DocMorris Overhauls Board to Strengthen Digital Health and Governance Expertise

DocMorris ( (CH:DOCM) ) has provided an update.

DocMorris AG plans a significant refresh of its Board of Directors at the 12 May 2026 Annual General Meeting, as long-serving members Stefan Feuerstein, Christian Mielsch and Rongrong Hu will not seek re-election after steering key strategic and digital phases. To support the company’s next development stage, the board is proposing the election of finance specialist Thomas Bucher, capital markets lawyer Thomas U. Reutter and AI and digital health expert Nicole Formica-Schiller, aiming to maintain a balanced mix of financial, governance and digital-health expertise.

The proposed appointments are designed to align DocMorris’ governance with its strategy of expanding as a leading digital health companion across Europe, reinforcing capabilities in corporate finance, regulation and AI-driven healthcare transformation. The company also confirmed its upcoming financial reporting and AGM timetable for 2026, underlining continuity in investor communication as it navigates leadership transition and ongoing digitalisation of its business model.

The most recent analyst rating on (CH:DOCM) stock is a Buy with a CHF12.00 price target. To see the full list of analyst forecasts on DocMorris stock, see the CH:DOCM Stock Forecast page.

More about DocMorris

DocMorris AG is a Swiss-listed digital health company operating leading online pharmacy, telemedicine and health-product marketplaces, with strong brands in Germany and several European markets. It serves around 11 million active customers via a highly automated logistics centre in the Netherlands, Germany’s largest telemedicine platform TeleClinic, and marketplaces in Southern Europe, generating CHF 1.186 billion in external sales in 2025.

Average Trading Volume: 306,869

Technical Sentiment Signal: Strong Sell

Current Market Cap: CHF248.4M

See more data about DOCM stock on TipRanks’ Stock Analysis page.